RC Medical's Venture Studio Model Targets Unmet Needs in Interventional Radiology

RC Medical is taking a different approach to medical device innovation, one that starts in the interventional suite rather than the engineering lab. The Lake Forest, California-based venture studio funds, designs, develops, and commercializes products for the interventional radiology market by partnering directly with physician-entrepreneurs. CEO David Ferrera recently outlined how the model works and why it matters for a field where clinical gaps often go unaddressed by traditional product roadmaps.

"We go to the interventional suite first," Ferrera said. "The physicians there see the gaps every week. Our job is to listen, then build the company around what they're actually describing." That physician-first orientation is the core of RC Medical's strategy. Instead of taking on contract work for outside clients, the studio identifies new technology and new indications for devices through direct collaboration with physicians, then forms a standalone company to carry each idea forward.

The studio model creates a clear division of labor. Physicians stay close to the clinical need, while RC Medical manages product development, funding, and the business structure required to commercialize the idea. "A physician knows the problem better than anyone," Ferrera said. "What we bring is the engineering, the regulatory path, and the discipline to turn that problem into something that can actually reach patients. Neither side can do it alone."

When an idea clears the early bar, RC Medical does not fold it into an existing product line. It forms a new company around it. "Each idea gets its own company, its own team, its own focus," Ferrera said. "A big portfolio company can lose a good idea in the shuffle. A newco can't afford to." That approach has produced three separate companies: Single Pass, Infinity Neuro, and Sonorous NV. Each grew out of a specific problem a physician described in the interventional suite and operates as its own business rather than a product line inside RC Medical.

Ferrera brings close to three decades of experience building devices for interventional neuroradiology and related fields, including co-founding Blockade Medical and serving as Chief Technology Officer of Balt Global. He said the lesson that carries over to RC Medical is that physicians in these procedures see problems that never make it into a traditional product roadmap. "A catheter that works in a textbook case can still fail in the specific anatomy a physician sees three times a week," he said. "That detail doesn't show up unless you're building with the physician, not for them."

The studio model is designed to catch that detail early, before a device design is locked in and hard to change. Ferrera acknowledged that the studio is not the right fit for every idea. "Some ideas are better as a feature of an existing product, not a new company," he said. "Part of the first conversation is being honest about which one this is." For ideas that do become a new company, the physician's involvement often continues through development and toward the market, keeping the clinical need in view at every stage.

For Texas, where medical device innovation and life sciences are growing, RC Medical's model offers a potential framework for translating clinical insight into commercial products. By forming dedicated companies around physician-identified gaps, the approach could accelerate the development of devices that address real-world procedural challenges, creating economic value and improving patient care. The studio's track record with three newcos suggests that the model can systematically bring overlooked ideas to market, a lesson that may resonate with entrepreneurs and investors across the state's medtech ecosystem.